Opus Genetics, Inc.

IRD

CIK 0001228627 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4M
↓-10.2% -$437Kvs FY2024 (Q4)
Gross Profit
$4M
↓-10.2% -$437Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
51/100
  • Profitability
    0ROIC -262.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 6.43 (above 1.5 = solid)
  • Leverage
    96D/E 0.07 (under 0.5 = conservative)
  • Efficiency
    10Asset Turnover 0.33x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -10.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -269.9% · trend +200.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$50M
everything owned
Total liabilities
$35M
everything owed
Stockholders' equity
$15M
shareholder claim
Net debt
$-44M
Net cash position ($44M)

Recent performance · 64 quarters

Revenue↓-10.2% -$437K
$4M
Net Income↓-131.9% -$10M
$-17M
Free Cash Flow↓-57.3% -$3M
$-9M
Operating Margin↓-62.8pts
-269.9%

Drill down